{"id":5109,"date":"2022-03-28T10:07:35","date_gmt":"2022-03-28T08:07:35","guid":{"rendered":"https:\/\/leo-foundation.org\/en\/?p=5109"},"modified":"2022-03-29T08:05:06","modified_gmt":"2022-03-29T06:05:06","slug":"annual-report-2021-reaching-milestones-that-shape-the-future","status":"publish","type":"post","link":"https:\/\/leo-foundation.org\/en\/2022\/03\/28\/annual-report-2021-reaching-milestones-that-shape-the-future\/","title":{"rendered":"Annual Report 2021: Reaching milestones that shape the future"},"content":{"rendered":"\n
28 March 2022<\/em><\/p>\n\n\n\n A transformational year characterized by several remarkable milestones and bold steps throughout the LEO Group. A year that was rounded off with philanthropic grants totaling DKK 163 million and a significant return of DKK 2,138 million on LEO Foundation\u2019s investing activities.<\/strong><\/strong><\/p>\n\n\n\n The Annual Report 2021 provides highlights of the LEO Foundation\u2019s three overarching areas: philanthropic activities, financial investments and engaged ownership.<\/p>\n\n\n\n Philanthropic activities<\/strong><\/p>\n\n\n\n The LEO Foundation’s overarching philanthropic commitment is to support skin research of the highest quality, in order to discover more about the skin, skin diseases and skin health.<\/p>\n\n\n\n Financial investments<\/strong><\/p>\n\n\n\n The main objectives of the LEO Foundation\u2019s financial investments are to ensure continued financial capability to support LEO Pharma\u2019s long-term continuation and strategic development, as well as provide funds for the Foundation\u2019s philanthropic activities.<\/p>\n\n\n\n Engaged ownership<\/strong><\/p>\n\n\n\n The LEO Foundation is the controlling shareholder of LEO Pharma. As an engaged owner, we aim to provide the company with the best possible platform for long-term development and success. Over the past years, we have carefully considered how to best support LEO Pharma\u2019s long-term objectives and ambitious growth strategy. This led to the decision to expand LEO Pharma\u2019s shareholder base. The LEO Foundation continues to be the majority owner of LEO Pharma.<\/p>\n\n\n\n LEO Pharma<\/strong><\/p>\n\n\n\n LEO Pharma took bold steps to deliver on its 2030 strategy and, importantly, received approval for tralokinumab in the EU and the US, bringing a new treatment to people suffering from moderate-to-severe atopic dermatitis. Its launch is expected to be an important driver of development in years to come and marks a major milestone for the company.<\/p>\n\n\n\n The full LEO Pharma results are available in the LEO Pharma Annual Report 2021 on the company\u2019s website<\/a>.<\/p>\n\n\n\n \u201cIt has been a transformational and challenging year throughout the LEO Group, and a year with notable milestones that have set us up well for 2022. Thank you to all LEO Group colleagues and board members, members of the skin research community who sit on our scientific funding committees, and to everyone whose work was supported by the LEO Foundation in 2022. It is your dedication that paves the way for curing skin diseases.\u201d<\/p>Peter Haahr, CEO, the LEO Foundation<\/cite><\/blockquote>\n\n\n\n
<\/a>